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The paradigm tripartite efflux transporter AcrA-AcrB-TolC confers multiple drug resistance to Escherichia
coli. Tikhonova et al. (2011) now examine how the three components connect to unity and highlight the critical
role of AcrA membrane proximal domain conformation for successful assembly.In Gram-negative bacteria, a clever net-
work of multidrug transporters, including
tripartite efflux systems that expel drugs
from the cytoplasm and periplasm to the
cell exterior, secure survival under antibi-
otic stress and lead as a result to the
occurrence of multidrug resistance. The
paradigm of a tripartite drug efflux system
is the Escherichia coli AcrA-AcrB-TolC
complex. This system is composed of
the membrane fusion protein (MFP) AcrA
and two membrane proteins: TolC,
a channel in the outer membrane, and
AcrB, a proton-dependent drug antiporter
of the inner membrane (Figure 1). This
multimodule efflux system only confers
drug resistance if all three partners are
present in the periplasmic space—i.e., it
is reliant on its Me´nage a` Trois.
X-ray structures of all three compo-
nents of the AcrA-AcrB-TolC system,
each elucidated individually but hitherto
not as a complex, have yielded enormous
insight in the atomic blueprints (Figure 1)
(Koronakis et al., 2000; Mikolosko et al.,
2006; Symmons et al., 2009; Murakami
et al., 2006; Seeger et al., 2006). These
structures and a substantial amount of
functional studies (NikaidoandTakatsuka,
2009) indicated that the inner-membrane
component AcrB acts as the motor for
the entire assembly, being a module
for both the energy transduction and
substrate specificity. The current hypoth-
esis suggests a three-stroke functional
rotation of the AcrB monomers, driven
by the proton-motive force, resulting in
the access, binding, and extrusion of
multiple drugs (Seeger et al., 2008).
The structures of the MFP AcrA and
its Pseudomonas aeruginosa homolog
MexA (Koronakis et al., 2000; Mikolosko
et al., 2006; Symmons et al., 2009) display
a multidomain polypeptide including
an a-helical hairpin, a lipoyl domain, ab-barrel domain, and the essential mem-
brane proximal (MP) domain tethered to
the inner membrane via a lipid anchor.
The latter three domains interact with
AcrB (Symmons et al., 2009), whereas
the a-helical hairpin is postulated to form
a coiled-coil interface with the TolC
a-barrel, a 100 A˚ conduit reaching into
the periplasmic space ready to interact
with the TolC docking domain of AcrB
(Figure 1).
However, the assembly process of the
three components AcrA, AcrB, and TolC
using the periplasmic space as a meeting
place is not understood. The outer
membrane channel TolC is used as
a substrate conduit by many (tripartite)
systems, sometimes in combination
with ABC-transporters, sometimes with
secondary H+ (or Na+)/substrate antiport-
ers belonging to the Major Facilitator
or Resistance Nodulation cell Division
superfamilies. Despite the TolC promis-
cuity, complex formation appears to be
highly regulated, depending not only on
TolC-MFP kinetics but also on MFP oligo-
merization kinetics and pH (Tikhonova
et al., 2009).
One recurring question is the stoichio-
metric composition of the tripartite
system. The high resolution structure of
TolC depicted an intrinsic trimer (Korona-
kis et al., 2000). Asymmetric as well as
symmetric structures of AcrB also reveal
a trimeric arrangement (Seeger et al.,
2008). However, the oligomeric state of
the MFP in complex with the membrane
components has been highly debated.
Crosslinking data combined with docking
experiments lead to the postulation of
a structure of a complete tripartite system
(Symmons et al., 2009), suggesting a
3:3:3 stoichiometry for AcrA-AcrB-TolC.
However, a recent structure of CusBA,
an inner-membrane component andChemistry & Biology 18, April 22, 2011MFP of a tripartite heavy metal efflux
system, shows a hexameric arrangement
of the MFP in the bipartite complex (Su
et al., 2011).
In this issue of Chemistry and Biology,
Tikhonova et al. (2011) tackle the question
of tripartite complex formation of AcrA-
AcrB-TolC, using mainly surface plasmon
resonance (SPR) analysis to obtain kinetic
data on the interactions between the
components involved.
Tikhonova et al. (2011) begin by
addressing the oligomeric state of AcrA.
They reveal a difference between the lipi-
dated form of AcrA, indicating dimer
formation,and the lipidanchor-lesssoluble
form that shows monomeric features.
Dimeric AcrA interacts with AcrB with an
affinity in the nanomolar range, whereas
the soluble monomeric version of AcrA
exhibits one order of magnitude lower
affinity to AcrB. This difference in affinity
is explained by higher stability of the MP
domain and dimerization of lipidated
AcrA.Their results support a6:3stoichiom-
etry of the bipartite AcrA:AcrB complex.
Interestingly however, AcrA-dimer forma-
tion and AcrA-AcrB interaction are highly
influenced by pH.
Until now, the dogma implied a sequen-
tial binding of AcrA with AcrB to recruit
TolC. However, from the current study, it
appears that TolC forms independent
interactions with AcrA as well as with
AcrB. It comes as a surprise that TolC
and AcrB form a high affinity complex
with a Kd value similar to the AcrA-AcrB
interaction. Even more astonishing is the
fact that the initial rate for AcrB-TolC inter-
action is higher than for the AcrA-AcrB
interaction. This finding strongly supports
a model of AcrA-independent preassem-
bly of TolCwith AcrB, a notion that contra-
dicts the previous perception that AcrA
is essential for TolC-AcrB interactionª2011 Elsevier Ltd All rights reserved 405
Figure 1. Me´nage a` Trois in the Periplasmic Space
AcrB (PDB entries: 1IWG, 2GIF) resides in the inner membrane (IM) and is composed of the transmembrane domain, the porter (pore) domain, and the TolC dock-
ing domain. TolC (PDB entry: 1EK9) is integrated into the outer membrane (OM) with its b-barrel domain and forms a long conduit in the periplasm by its a-helical
domain, which narrows to a closed entrance at the proximal end. AcrA (2F1M, shown is the MexA homolog structure [2V4D] including the membrane proximal
[MP] domain) is divided into the membrane proximal domain, b-barrel domain, the lipoyl domain, and the a-helical hairpin. AcrA is associated with the inner
membrane via an N-terminally attached lipid anchor. The assembly of the components in the periplasmic space leads to a functional tripartite system lending
Gram-negative cells the ability to resist toxic compound (e.g. antibiotics) stress. Adapted and modified from Symmons et al (2009), Seeger et al. (2008), and
Eswaran et al. (2004).
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Previews(Symmons et al., 2009). The single com-
ponents interact with each other upon
a sequential presentation, demonstrating
that the bipartite AcrA-AcrB or TolC-
AcrB preassembly is favorable for final
tripartite complex formation. This process
occurs independently of the presence of
efflux pump substrates.
Another interesting finding is the influ-
ence of the pH at various stages of
in vitro complex formation. Not only do
rate constants and affinities change
upon a pH downshift, but also the under-
lying reaction models show pH-depen-
dent variations by shifting from simple to
more complex kinetics that account for
conformational changes upon initial asso-
ciation events. In this process, there may
be a key role for the MP domain, as Tikho-
nova et al. (2011) show that conforma-
tional changes are most likely to occur in
this AcrA domain during complex forma-
tion. This foreshadows the notion that
subsequent processes following the initial
complex formation will play an important406 Chemistry & Biology 18, April 22, 2011 ªrole to obtain the final drug transporting
assembly (Figure 1).
Perhaps most interesting is the ques-
tion of how these findings can be extrap-
olated to in vivo complex formation. Since
the proton concentration in the periplasm
is thought to be in equilibrium with the
outside pH, how are AcrA-AcrB interac-
tions influenced? Lipid modification of
AcrA is facilitating complex formation,
a process involving the MP domain while
it is in close proximity to the inner-
membrane surface. How is the charge of
the inner membrane lipids and maybe
even the local proton concentration so
close to the membrane surface influ-
encing AcrA stability and its interaction
potential with the other components of
the tripartite system?
Tikhonova et al. (2011) present unprec-
edented extensive biophysical analysis
on the individual components of the para-
digm tripartite AcrA-AcrB-TolC complex
of E. coli. The results are indeed utmost
valuable for understanding tripartite2011 Elsevier Ltd All rights reservedcomplex formation and open up new
intriguing questions.
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Activity-based protein profiling (ABPP) is emerging as a game-changing tool for drug discovery, target
validation, and basic biology. In this issue, Chang et al. (2011) report the ABPP-facilitated discovery of
JW480, a highly selective potent and orally bioavailable inhibitor of monoalkylglycerol ether hydrolase
KIAA1363 that dramatically impairs in vivo growth of human prostate cancer cell lines.Identification and characterization of the
functionally diverse enzyme complexes
that coordinate and control all cellular
processes is among the most important
challenges of the postgenomic era. Quan-
titative understanding of dynamic enzyme
activity, integrated from the cell up to
the whole organism, is an essential step
towardaunifiedmodel of life, andapower-
ful tool in the increasingly complex search
for viable drug targets across all diseases.
To understand enzyme function, we must
decipher the emergent chemistry of
proteins, and the application of chemical
technologies to this challenge has proven
particularly powerful, giving rise to the
vibrant multidiscipline of chemical proteo-
mics. An ultimate objective of this
emerging field is to profile all types of
enzymatic activity in whole organisms,
a process commonly termed Activity-
Based Protein (or Proteome) Profiling
(ABPP), presenting some fascinating chal-
lenges in chemical biology (Heal et al.,
2011). ABPP has origins in work from the
1980s, labeling theactive siteofproteases,
but it is only recently that it has matured
into a versatile andpowerful platform tech-
nology. The Cravatt laboratory is a recog-
nizedABPPpioneer, havingdemonstrated
profiling across a remarkably broad range
of enzyme classes. In a notable recent
study, a search for selective inhibitors ofmembers of the serine hydrolase (SH)
superfamily (Bachovchin et al., 2010) was
implemented using competitive ABPP, in
which synthetic molecules compete with
the probe for binding to the target enzyme.
In this case, an SH-directed fluorophosph-
onate-rhodamine (FP-Rh) probe was used
to profile over 70 hydrolases against more
than 150 carbamate inhibitors, ultimately
resulting in compounds selective toward
single or small groups of SHs. Competitive
ABPP is a perfect fit to the aspirations of
modern drug discovery, allowing fine
tuning of inhibitor selectivity and potency
against numerous enzymes in parallel,
directly in the native complexity of the
proteome. Furthermore, even inhibitors
that are selective for or against uncharac-
terized enzymes for which substrates
have not yet been reported can be devel-
oped utilizing this methodology. The impli-
cations for understanding inhibitor on- and
off-targets in vivo during drug develop-
ment are evident, and ABPP holds great
promise for avoiding drug attrition due to
toxicity or efficacy failures in late-stage
clinical trials.
In the current issue, Ben Cravatt and
coworkers (Chang et al., 2011) report the
development of JW480, a potent and
selective carbamate-based inhibitor of
KIAA1363 (also known as AADACL1),
which is a membrane-bound 2-acetylmonoalkylglycerol ether hydrolase. KIAA
1363 is a member of the aforementioned
abundant and diverse SH superfamily,
which includes esterases, thioesterases,
lipases, amidases, and proteases. Sev-
eral SHs are implicated in the develop-
ment and progression of tumors (Nomura
et al., 2010a), but unfortunately the bio-
logical and physiological functions for
many of these potential pharmacological
targets remain poorly understood (Simon
and Cravatt, 2010). Increased activity of
KIAA1363 results in the overproduction
of monoalkylglycerol ethers (MAGEs),
which in turn are converted into lyso-
phospholipids that stimulate survival,
mobility, and aggressiveness of cancer
cells (Chiang et al., 2006). KIAA1363 is
the second SH enzyme reported recently
by the same group to lead to overproduc-
tion of protumorigenic lipids. In the former
study, a combination of ABPP, proteomic,
and lipidomic analyses revealed a key role
for monoacylglycerol lipase (MAGL) in
leveling these fats (Nomura et al., 2010b).
The current study evolves from this
work, focusing on the KIAA1363-MAGE
pathway in prostate cancer cells with
recently discovered lead compounds
(Bachovchinetal., 2010), providingastart-
ing point for rational design ofmore potent
and selective analogs. In initial experi-
ments, increased activity of KIAA1363,ª2011 Elsevier Ltd All rights reserved 407
